In Vitro Diagnostics Business Outlook, Volume 3, Issue 5 - Point-of-Care (POC)

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,995	35 Pages	Kalorama Information	October, 2024	KLI19272151

Best Price Guarantee
Price	from $4,995
Length	35 Pages
Publisher	Kalorama Information
Published Date	October, 2024
SKU	KLI19272151

In Vitro Diagnostics Business Outlook, Volume 3, Issue 5 - Point-of-Care (POC)

(price includes 6 issues published every two months)In Vitro Diagnostics Business Outlook is a bimonthly publication with six issues annually.

In Vitro Diagnostics Business Outlook offers information and data that you cannot get anywhere else, including:

Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities

A comprehensive view of the IVD market with test categories covered and company briefs
M&A activities, selected partnerships & collaborations, partnership deals, and more
Industry & region watch to help tailor strategies
Analysis of news and events and reporting on news not easily available

MARKET ANALYSIS: IVD POC TESTING: OVERVIEW OF IVD POC TESTING; MARKET OUTLOOK; Table: Global POC Diagnostic Market, by Broad Segment, 2024 and 2029 ($ million) (professional testing, self-testing); Figure: Point-of-Care Diagnostics (COVID-19 vs. non-COVID testing), 2020-2024 ($ million); Figure: Global POC Diagnostic Market Distribution, by Segment, 2024 (%) (Cardiac Care; Coagulation; Critical Care; Drug of Abuse; Fecal Occult Blood; Glucose; Hematology; Infectious Disease Lipid [Cholesterol]; Pregnancy/Fertility; Urinalysis; Others); Selected Product Activity; REGIONAL MARKET; Figure: POC Diagnostics Market Value, by Global Region, 2024 ($ million) (North America, Europe, Asia Pacific, Latin America, Middle East, Africa); COMPANY BRIEFS; Abbott Diagnostics; Dexcom; Roche
EXECUTIVE NEWS BRIEFING: BRIEFS; Quanterix Appoints New Member to Board of Directors; Beckman Coulter Appoints New President; MARAbio Raises $19 Million in Series A Funding; Amprion Makes Advances in Series B Financing; Sunbird Bio Closes $14 Million Financing Round; Bruker Reported 17% Growth in Second Quarter 2024 and 11% Growth for the First Six Months; Figure: Bruker Corporation Sales, by Business, H1 2023 Compared to H1 2024 (Bruker BioSpin, Bruker CALID, Bruker Nano, BEST, Eliminations); Figure: Bruker CALID Quarterly Performance, Sales by Quarter, Q1 2022 - Q2 2024; Figure: Bruker Corporation H1 2023 and H1 2024 Regional Sales Breakdown Distribution (Asia Pacific, Japan; Europe; United States; Other); Myriad Genetics Reports 13% Revenue Growth in First Half 2024; Table: Myriad Genetics Revenue Mix, by Product, H1 2023 vs H1 2024 ($ million) (Hereditary Cancer; Pharmacogenomics; Prenatal; Tumor Profiling); Figure: Myriad Genetics Revenue Mix, by Business Unit, Quarterly Performance Q1 2023 through Q2 2024 ($ million) (Mental Health, Oncology, Women’s Health)
DIAGNOSTIC MARKET MERGERS, ACQUISITIONS AND PARTNERSHIP DEALS: PARTNERSHIPS AND COLLABORATIONS; MERGERS AND ACQUISITIONS; Table: Recent Diagnostic Market Mergers, Acquisitions and Partnership Deals
INDUSTRY WATCH: INDUSTRY WATCH COVID-19/FLU UPDATE
REGION WATCH: FINLAND; Figure: Finland GDP Value and Growth, by Year, 2013-2023 ($ billion); Figure: Finland Social Protection Expenditure by Function, 1995-2022 in 2022 Prices (€ billion); Figure: Finland IVD Market, 2019-2024 ($ million)
BROAD-BASED COMPANY ANNOUNCEMENTS: ANNOUNCEMENTS; Roche Launches TAGS Technology Test; Exact Sciences Welcomes New Cologuard Plus Test; PreAnalytiX Launches PAXgene Urine Liquid Biopsy Set; Abionic Launches Early Sepsis Test; QIAGEN Expands Liquid Biopsy Portfolio; FoundationOne Gains Liquid CDx Approval; Revvity’s Euroimmun Announces Groundbreaking Launch in the EU